Результаты поиска

Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.

Cancer-associated venous thromboembolism (CA-VTE) is a significant complication in oncology, contributing to morbidity, mortality, and increased healthcare utilization. Due to multiple patient- and disease-related factors, patients with cancer are at a markedly elevated risk for VTE, particularly within the first 6 months of diagnosis. The aim of this review is to provide an overview of current challenges and unmet needs in CA-VTE prediction, prevention and management. While the Khorana score remains the most widely used risk stratification tool, its limited sensitivity has prompted the develo

Совпадение в полном тексте источника
… Treatment with low molecular weight heparin (nadroparin or semuloparin) has previously been shown to reduce VTE rates in ambulatory cancer patients on systemic chemotherapy [ 99 , 100 ]. … Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study Lancet Oncol. 2009 10 943 949 10.1016/S1470-2045(09)70232-3 19726226 100. Agnelli G. …

Chemotherapy-induced bowel ischemia: diagnostic imaging overview.

Cancer patients need multimodal therapies to treat their disease increasingly. In particular, drug treatment, as chemotherapy, immunotherapy, or various associations between them are commonly used to increase efficacy. However, the use of drugs predisposes a percentage of patients to develop toxicity in multiple organs and systems. Principle chemotherapy drugs mechanism of action is cell replication inhibition, rapidly proliferating cells especially. Immunotherapy is another tumor therapy strategy based on antitumor immunity activation trough agents as CTLA4 inhibitors (ipilimumab) or PD-1/PD-

Совпадение в полном тексте источника
… Barni S Labianca R Agnelli G Bonizzoni E Verso M Mandalà M Brighenti M Petrelli F Bianchini C Perrone T and Gasparini G Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study Journal of Translational …

Cancer-associated thrombosis: clinical presentation and survival.

BackgroundThromboembolic events are important causes of morbidity and mortality in cancer patients. Clinical presentation in a community-based setting has not been fully clarified. The purpose of this study was to evaluate the incidence, risk factors, role of thrombophilia, and subsequent survival following thrombosis in cancer patients.MethodsA retrospective review was undertaken of clinical data for all consecutive patients with histologically confirmed cancer seen by the author at a regional cancer center, with emphasis on cancer-related thrombosis.ResultsBetween 2005 and 2012, of 1874 canc

Совпадение в полном тексте источника
… Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–949. doi: 10.1016/S1470-2045(09)70232-3. 11. …

Management of venous thromboembolism in patients with cancer: role of dalteparin.

Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relatio

Совпадение в полном тексте источника
… Comparison of the pharmacokinetic profiles of three low molecular mass heparins – dalteparin, enoxaparin and nadroparin – administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism) Thromb Haemost. 1995;73:630–40. Couban S, Goodyear M, Burnell M, et al. …

A study on a real-world data-based VTE risk prediction model for lymphoma patients.

BackgroundPatients diagnosed with malignant tumors exhibit a markedly elevated risk of venous thromboembolism (VTE), which has a negative impact on their prognosis. Currently, there is no reliable predictive model specifically for thrombosis risk in lymphoma patients. This study aims to develop and validate a machine learning model leveraging real-world data, offering a dependable risk assessment tool for the early identification of VTE in lymphoma patients.MethodsWe retrospectively analyzed 605 hospitalized patients with lymphoma between January 2019 and June 2024. Candidate predictors includ

Совпадение в полном тексте источника
… Low molecular weight heparin (LMWH) drugs such as enoxaparin and nadroparin are currently the drugs of choice for prophylactic anticoagulant therapy. LMWHs exert their antithrombotic effect through selective inhibition of factor Xa and factor IIa, effectively interrupting the coagulation cascade. …

Aspirin Versus LMWH for Thromboprophylaxis Following Hip or Knee Arthroplasty-Clinical Implications and Budget Impact.

Venous thromboembolism (VTE) remains a significant concern for patients undergoing hip or knee arthroplasty, with a need to balance effective thromboprophylaxis and bleeding risk. We aimed to compare the efficacy, safety, and budget impact of aspirin versus low-molecular-weight heparin (LMWH) as sole thromboprophylactic agents initiated immediately postoperatively in this population. First, we conducted a systematic review of randomized controlled trials (RCTs) from Ovid MEDLINE, Embase, and Cochrane CENTRAL databases, assessing clinical outcomes and healthcare costs. Subsequently, a simplifie

Совпадение в полном тексте источника
… The search terms included “aspirin,” “LMWH” or “enoxaparin” or “dalteparin” or “tinzaparin” or “nadroparin,” “orthopedic surgery” or “arthroplasty” or “knee arthroplasty” or “hip arthroplasty,” and “thromboembolism” or “thromboprophylaxis” or “thrombosis.” …

Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.

Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance. The latter is achieved through various cellular mechanisms that ultimately circumvent the pharmaceutical's mode of action. The need for novel therapeutic approaches is necessary under these circumstances. An

Совпадение в полном тексте источника
… | NCT00166725 | II | 1 February 2004 | 40 | Completed | Octreotide acetate Anticoagulant | Standard Therapy with or Without Dalteparin in Treating Patients with Advanced Breast, Lung, Colorectal, or PCa | NCT00003674 | III | 1 December 1998 | 141 | Completed | Dalteparin Anticoagulant | Effects of Nadroparin … in Patients with Lung, Pancreas or PCa | NCT00312013 | III | 1 May 2006 | 503 | Completed | Nadroparin Synthetic retinoid | Fenretinide In Treating Patients with Advanced or Metastatic Hormone-Refractory Prostate Cancer | NCT00077402 | II | 1 February 2004 | 50 | Completed | Fenretinide Other | Preoperative …

Economic Burden of Intravenous Decitabine Administration in Patients Affected by Acute Myeloid Leukemia Ineligible for Induction Chemotherapy and Impact of Oral Formulation Introduction: A Micro-Costing Study in Italy.

PurposeIntravenous (IV) decitabine is a therapeutic option for patients with newly diagnosed acute myeloid leukemia (AML) ineligible for induction chemotherapy. Recently, the oral formulation of decitabine-cedazuridine demonstrated comparable efficacy and safety to IV decitabine, and pharmacokinetic equivalence. This study estimates the direct non-drug healthcare costs of IV decitabine administration in Italy, including central venous catheter (CVC) and infection management, and assesses the economic impact of oral decitabine introduction.MethodsA micro-costing analysis from the Italian Nation

Совпадение в полном тексте источника
… Cost analysis of thromboprophylaxis in patients at high thromboembolic risk with enoxaparin, dalteparin and nadroparin in Colombia: a systematic literature review-based study . CEOR . 2024 ; Volume 16 : 813 – 825 . doi: 10.2147/CEOR.S472192 PMC11556238 39534668 76. Preliminary Otsuka data on file. …

Профилактика и лечение венозного тромбоэмболия у пациентов с множественной миеломой: руководящие принципы клинической практики от имени Европейской сети миеломы.

Венозный тромбоэмболизм (VTE) является частым осложнением у пациентов с множественной миеломой (MM), что приводит к повышению заболеваемости, смертности, прерыванию лечения и снижению качества жизни. Основные рекомендации включают следующее: Информирование пациентов о риске ВТЕ и признаках/симптомах тромбоза глубокой вены и легочной эмболии. Специализированная помощь. - создание специализированного диагностического и лечебного механизма для профилактики и лечения ВТЕ в амбулаторных условиях. Оценка рисков. Регулярная оценка риска VTE с использованием подтвержденных оценок. Первичная тромбопроф

Совпадение в полном тексте источника
… Nadroparin | ≤70 kg: 3800 anti‐Xa IU sc o.d. >70 kg: 5700 anti‐Xa IU sc o.d. | 86 anti‐Xa IU/kg every 12 h, or 171 anti‐Xa IU/kg o.d. | 86 anti‐Xa IU/kg every 12 h, or 171 anti‐Xa IU/kg o.d. Bemiparin | | 115 anti‐Xa IU/kg o.d. | 115 anti‐Xa IU/kg o.d. …

42nd International Symposium on Intensive Care & Emergency Medicine

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban.

Cancer-associated venous thromboembolism (VTE) is a frequent, potentially life-threatening event that complicates cancer management. Anticoagulants are the cornerstone of therapy for the treatment and prevention of cancer-associated thrombosis (CAT); factor Xa-inhibiting direct oral anticoagulants (DOACs; apixaban, edoxaban, and rivaroxaban), which have long been recommended for the treatment of VTE in patients without cancer, have been investigated in this setting. The first randomized comparisons of DOACs against low-molecular-weight heparin for the treatment of CAT indicated that DOACs are

Совпадение в полном тексте источника
… Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo‐controlled, double‐blind study. Lancet Oncol. 2009;10:943–9. 51. Kimpton M, Wells PS, Carrier M. …

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.

The International Initiative on Thrombosis and Cancer is an independent academic working group of experts aimed at establishing global consensus for the treatment and prophylaxis of cancer-associated thrombosis. The 2013, 2016, and 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines have been made available through a free, web-based mobile phone application. The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19. Key recommendations (grade 1A or 1B) include: (1)

Совпадение в полном тексте источника
… j.ejca.2011.10.017 67 Pelzer U Opitz B Deutschinoff G Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial J Clin Oncol 33 2015 2028 2034 25987694 10.1200/JCO.2014.55.1481 68 Agnelli G Gussoni G Bianchini C Nadroparin …

Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors.

The incidence of cancer-associated thrombosis has increased in recent years. While the association between venous thromboembolism (VTE) and chemotherapy is well established, there is no clear link between immune checkpoint inhibitors (ICIs) and VTE risk. Many risk assessment models (RAMs) have been developed to identify high-risk patients who need prophylaxis. However, these models are validated in patients undergoing chemotherapy, while they are scarce in those receiving immunotherapy. Moreover, the mechanisms linking ICIs to thrombosis are still a matter of debate. They include the upregulat

Совпадение в полном тексте источника
… Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: Results of a retrospective analysis of the PROTECHT study J. Transl. Med. 2011 9 179 10.1186/1479-5876-9-179 22013950 PMC3220644 36. Verso M. Agnelli G. Barni S. Gasparini G. Labianca R. …

Anticoagulation for Cancer Patients in Special Situations: A Narrative Review of Guidelines and Literature.

Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. The management of special situations-including recurrent venous thromboembolism (VTE), thrombosis at unusual sites, and central venous catheter-associated thrombosis (CVC-AT)-remains particularly challenging because of the limited availability of high-quality evidence. This narrative review synthesizes recommendations from major international and Spanish clinical practice guidelines and expert consensus documents, including those from SEOM, ESMO, ASCO, NCCN, ITAC and SEMI, to provide a struc

Sex Differences in Cancer-Associated Thrombosis.

Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in oncology, arising from complex interactions between tumor biology, host factors, and anticancer therapies. Growing evidence indicates that biological sex and gender-related factors modulate both thrombotic risk and clinical expression of venous thromboembolism (VTE) in patients with cancer. In this narrative review, we summarize current epidemiological, biological, and clinical data on sex- and gender-related differences in CAT across solid and hematologic malignancies. Men generally exhibit a higher overall inci

Совпадение в полном тексте источника
… Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: Results of a retrospective analysis of the PROTECHT study. J. Transl. Med. 2011;9:179. doi: 10.1186/1479-5876-9-179. 54. …

Abstracts from the 8th Drug Hypersensitivity Meeting (DHM)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

15th Конгресс Европейской ассоциации клинической фармакологии и терапии (ЕАКПТ)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.

In cancer patients, thrombocytopenia can result from bone marrow infiltration or from anticancer medications and represents an important limitation for the use of antithrombotic treatments, including anticoagulant, antiplatelet, and fibrinolytic agents. These drugs are often required for prevention or treatment of cancer-associated thrombosis or for cardioembolic prevention in atrial fibrillation in an increasingly older cancer population. Data indicate that cancer remains an independent risk factor for thrombosis even in case of thrombocytopenia, since mild-to-moderate thrombocytopenia does n

Артериальный тромбоэмболизм

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstract

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.